BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9890197)

  • 1. Increased circulating soluble form of Fas in patients with dilated cardiomyopathy.
    Kawakami H; Shigematsu Y; Ohtsuka T; Okayama H; Hayashi Y; Hara Y; Kodama K; Hamada M; Hiwada K
    Jpn Circ J; 1998 Dec; 62(12):873-6. PubMed ID: 9890197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy.
    Zen K; Irie H; Doue T; Takamiya M; Yamano T; Sawada T; Azuma A; Matsubara H
    Int Heart J; 2005 Mar; 46(2):231-44. PubMed ID: 15876807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction.
    Ohtsuka T; Hamada M; Sasaki O; Suzuki M; Hara Y; Shigematsu Y; Ohtani T; Honda T; Hiwada K
    Coron Artery Dis; 1999 Jun; 10(4):221-5. PubMed ID: 10376200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
    Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
    J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
    Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
    Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble antiapoptotic molecules and immune activation in chronic heart failure and unstable angina pectoris.
    Fiorina P; Astorri E; Albertini R; Secchi A; Mello A; Lanfredini M; Craveri A; Olivetti G; Quaini F
    J Clin Immunol; 2000 Mar; 20(2):101-6. PubMed ID: 10821461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
    Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
    J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.
    Jodo S; Kobayashi S; Nakajima Y; Matsunaga T; Nakayama N; Ogura N; Kayagaki N; Okumura K; Koike T
    Clin Exp Immunol; 1998 May; 112(2):166-71. PubMed ID: 9649177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum levels of soluble Fas in progressive B-CLL.
    Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
    Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy.
    Parissis JT; Adamopoulos S; Karatzas D; Paraskevaidis J; Livanis E; Kremastinos D
    Eur J Cardiovasc Prev Rehabil; 2005 Apr; 12(2):164-8. PubMed ID: 15785303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy.
    Liang QL; Li ZY; Chen GQ; Lai ZN; Wang BR; Huang J
    J Zhejiang Univ Sci B; 2010 Dec; 11(12):912-7. PubMed ID: 21121068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Omentin-1 Levels Are Decreased in Dilated Cardiomyopathy Patients with Overt Heart Failure.
    Huang Y; Lin Y; Zhang S; Wang Z; Zhang J; Chang C; Liu L; Ji Q; Liu X
    Dis Markers; 2016; 2016():6762825. PubMed ID: 27313334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
    Konno R; Takano T; Sato S; Yajima A
    Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
    Kawahito K; Misawa Y; Fuse K
    Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
    Adamopoulos S; Parissis JT; Georgiadis M; Karatzas D; Paraskevaidis J; Kroupis C; Karavolias G; Koniavitou K; Kremastinos DT
    Am Heart J; 2002 Aug; 144(2):359-64. PubMed ID: 12177657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly.
    Seishima M; Takemura M; Saito K; Sano H; Minatoguchi S; Fujiwara H; Hachiya T; Noma A
    Clin Chem; 1996 Dec; 42(12):1911-4. PubMed ID: 8969625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
    Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
    Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
    Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
    Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
    Knipping E; Krammer PH; Onel KB; Lehman TJ; Mysler E; Elkon KB
    Arthritis Rheum; 1995 Dec; 38(12):1735-7. PubMed ID: 8849344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.